Doug A Gouchoe
Overview
Explore the profile of Doug A Gouchoe including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
14
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
2.
Adaptive Chest Cavity Expansion Following Lung Allograft Oversizing in Idiopathic Pulmonary Fibrosis
Gouchoe D, Botros M, Satija D, Roberts S, Applegate B, Clark A, et al.
J Surg Res
. 2025 Feb;
305:295-303.
PMID: 39937562
Introduction: Due to parenchymal fibrosis and chest wall contraction in idiopathic pulmonary fibrosis (IPF), donor lung allografts are generally undersized to accommodate smaller diseased chest cavities. We hypothesized that transplanting...
3.
Satija D, Gouchoe D, Monasterio J, Cui E, Lilly S, Boudoulas K, et al.
J Surg Res
. 2024 Dec;
305:222-230.
PMID: 39724685
Introduction: Transcatheter aortic valve replacement (TAVR) has become a viable alternative to surgical aortic valve replacement (SAVR) for high-risk patients with aortic stenosis. One such high-risk group is patients with...
4.
Gouchoe D, Satija D, Cui E, Schroder J, Milano C, Bishawi M, et al.
J Thorac Cardiovasc Surg
. 2024 Dec;
PMID: 39662604
Background: Normothermic regional perfusion (NRP) and direct procurement and perfusion (DPP) allow for transplantation with donation after circulatory death (DCD) hearts. This study aimed to characterize the use of and...
5.
Gouchoe D, Cui E, Satija D, Heh V, Darcy C, Henn M, et al.
Ann Thorac Surg
. 2024 Nov;
119(3):651-659.
PMID: 39549948
Background: Allografts from donation after circulatory death (DCD) or brain death donors may be evaluated by ex vivo lung perfusion (EVLP) to assess quality for transplantation. We sought to determine...
6.
Gouchoe D, Zhang Z, Kim J, Lee Y, Whitson B, Zhu H
Med Rev (2021)
. 2024 Oct;
4(5):384-394.
PMID: 39444796
Lung transplantation is the only definitive therapy for end-stage pulmonary disease. Less than 20 % of offered lungs are successfully transplanted due to a limited ischemic time window and poor...
7.
Gouchoe D, Satija D, Cui E, Aly A, Henn M, Choi K, et al.
Artif Organs
. 2024 Aug;
48(12):1458-1466.
PMID: 39165095
Background: The purpose of this study was to identify the association of increasing ischemic times in recipients who receive lungs evaluated by ex vivo lung perfusion (EVLP) and their association...
8.
Gouchoe D, Satija D, Cui E, Ferrari-Light D, Henn M, Choi K, et al.
Artif Organs
. 2024 Aug;
48(12):1467-1475.
PMID: 39135423
Background: Ex vivo lung perfusion (EVLP) conducted outside of the transplant center has increased in recent years to mitigate its limitation by resources and expertise. We sought to evaluate EVLP...
9.
Gouchoe D, Cui E, Satija D, Henn M, Choi K, Rosenheck J, et al.
J Clin Med
. 2024 Aug;
13(15).
PMID: 39124711
Primary graft dysfunction (PGD) has detrimental effects on recipients following lung transplantation. Here, we determined the contemporary trends of PGD in a national database, factors associated with the development of...
10.
Scott S, Gouchoe D, Azap L, Henn M, Choi K, Mokadam N, et al.
Curr Cardiovasc Risk Rep
. 2024 Aug;
18(7):95-113.
PMID: 39100592
Purpose Of Review: Despite efforts to curtail its impact on medical care, race remains a powerful risk factor for morbidity and mortality following cardiac surgery. While patients from racial and...